Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

TC BioPharm (TCBP) has announced the pricing of its public offering at $2 per ADS, aiming to raise $3.5 million through the sale of 1,750,000 ADS.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:15 pm

Despegar.com, Corp. (DESP) shares rose by 16.4% after raising its FY23 revenue guidance. Other stocks moved in Wednesday's mid-day session with significant gainers including Shattuck Labs (STTK), ReShape Lifesciences (RSLS), and C4 Therapeutics (CCCC), among others. Losers included Hywin Holdings (HYW), Boqii Holding (BQ), and Processa Pharmaceuticals (PCSA). Notable mentions include ABM Industries (ABM) with positive results and guidance, and Take-Two Interactive Software (TTWO) being added to the Nasdaq-100 Index.

Portfolio Pulse from Avi Kapoor

December 13, 2023 | 6:40 pm

TC BioPharm announced a change in the ratio of its ADSs to ordinary shares. Effective December 15, 2023, each ADS will represent 20 ordinary shares, a change from the current 1:1 ratio.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:34 am

In Monday's pre-market session, several healthcare stocks experienced significant movements. Pasithea Therapeutics (KTTA) saw a sharp rise of 86.6%, while Assure Holdings (IONM) and Poseida Therapeutics (PSTX) also saw substantial gains. On the downside, Cogent Biosciences (COGT) and X4 Pharmaceuticals (XFOR) faced notable declines. These movements reflect changes in investor sentiment and could be driven by recent company news, market trends, or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 1:06 pm

Cerevel Therapeutics Holdings, Inc. (CERE) shares surged approximately 15% in pre-market trading after AbbVie Inc. (ABBV) announced plans to acquire Cerevel for $8.7 billion, or $45 per share in cash. The acquisition is expected to close in mid-2024. Other stocks experienced pre-market movements, with notable gainers including Hempacco Co., Inc. (HPCO), MicroAlgo Inc. (MLGO), and AerSale Corporation (ASLE), and significant losers such as ZyVersa Therapeutics, Inc. (ZVSA), Red Cat Holdings, Inc. (RCAT), and Chewy, Inc. (CHWY).

Portfolio Pulse from Avi Kapoor

December 07, 2023 | 12:59 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. SenesTech (SNES) saw a 42.0% increase, while Centessa Pharmaceuticals (CNTA) dropped by 10.6%. Other notable gainers include TC BioPharm (TCBP), Heart Test Laboratories (HSCS), UpHealth (UPH), AcelRx Pharmaceuticals (ACRX), and Sientra (SIEN). On the losing side, Redhill Biopharma (RDHL), OneMedNet (ONMD), Tharimmune (THAR), Envoy Medical (COCH), and Leap Therapeutics (LPTX) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 9:31 pm

Anavex Life Sciences Corp. (AVXL) shares dropped by 10% after reporting a Q4 net loss of $10.1 million, or 12 cents per share, compared to a net loss of $14.3 million, or 18 cents per share, in the same period last year. Other stocks experienced significant movements in Monday's mid-day session, with notable gainers including RedHill Biopharma Ltd. (RDHL), Biodexa Pharmaceuticals Plc (BDRX), and Tharimmune, Inc. (THAR), among others. Losers included 10X Capital Venture Acquisition Corp. II (VCXA), BioNexus Gene Lab Corp. (BGLC), and HCW Biologics Inc. (HCWB). Affirm Holdings, Inc. (AFRM) saw a jump of 13.7% following positive 'buy now, pay later' predictions for Cyber Monday.

Portfolio Pulse from Lisa Levin

November 27, 2023 | 6:41 pm

TC Biopharm's stock price has risen following the announcement that the FDA has cleared the Phase 1B Investigational New Drug (IND) application for TCB-008, a treatment for Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:47 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Mira Pharmaceuticals, TC BioPharm, Panbela Therapeutics, Estrella Immunopharma, Bio-Path Holdings, and MyMD Pharmaceuticals were among the gainers, with increases ranging from 7.14% to 9.2%. Conversely, Impel Pharmaceuticals, Avenue Therapeutics, Cyclacel Pharmaceuticals, Alaunos Therapeutics, Evoke Pharma, and Scholar Rock Holding were the losers, with their stock prices falling between 7.07% and 20.9%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 9:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Telesis Bio (TBIO) saw a 32.5% increase, while vTv Therapeutics (VTVT) faced a sharp 96.8% decline. Other notable gainers include Femasys (FEMY), Medigus (MDGS), TC BioPharm (TCBP), Assembly Biosciences (ASMB), and PaxMedica (PXMD). On the losing side, Impel Pharmaceuticals (IMPL), Aethlon Medical (AEMD), Ikena Oncology (IKNA), Biophytis (BPTS), and Heart Test Laboratories (HSCS) saw declines ranging from 10.56% to 31.96%.

Portfolio Pulse from Benzinga Insights

November 24, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.